Avacen Medical Wins Innovation Award for Fibromyalgia Pain Control Device

Avacen Medical Wins Innovation Award for Fibromyalgia Pain Control Device
Avacen Medical has received an innovation award for a dry heat device it invented to treat the pain that is widespread in fibromyalgia. The global consulting firm Frost & Sullivan gave Avacen its European New Product Innovation Award for developing the Avacen 100. The consultant, which is based in the technology center of Mountain View, California, made the award after analyzing all of the fibromyalgia management devices that are available in Europe. Frost & Sullivan presents the annual award to a company that uses cutting-edge technology to create an important product. In addition to technology consulting, it offers business strategy and other consulting services. “The treatment of fibromyalgia remains challenging, and the underlying pathology is poorly understood," Brahadeesh Chandrasekaran, an industry analyst at Frost & Sullivan, said in a press release. "There is a need for alternative non-invasive treatments or adjunct therapy that can help alleviate pain in fibromyalgia patients," he said. "Device-based therapies are important since a placebo-controlled study showed that fibromyalgia patients reported modest improvements in pain, tender points, fatigue, and sleep after electro-stimulation." Avacen sells the Avacen 100 in the United States to relieve arthritis joint pain and relax muscles. Both the European Union and Canada approved the Avacen 100 this year for managing fibromyalgia pain. The EU bestowed its 
Subscribe or to access all post and page content.